Current and novel antibiotics against resistant Gram-positive bacteria

Review

(4427) Views  (2247) Full article downloads

Authors: Federico Perez, Robert A Salata, Robert A Bonomo

Published Date September 2008 Volume 2008:1 Pages 27 - 44

DOI: http://dx.doi.org/10.2147/IDR.S3545

Federico Perez¹, Robert A Salata¹, Robert A Bonomo²

¹Division of Infectious Diseases and HIV Medicine, University Hospitals Case Medical Center, Cleveland OH, USA; ²Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA

Abstract: The challenge posed by resistance among Gram-positive bacteria, epitomized by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new generation of antimicrobials. This review focuses on the new β-lactams with activity against MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, and telavancin). It will also consider the role of vancomycin in an era of existing alternatives such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are described, such as iclaprim, friulimicin, and retapamulin, among others.

Keywords: Gram-positive bacteria, vancomycin, anti-MRSA cephalosporins, lipoglycopeptides, daptomycin, linezolid, tigecycline